Protara Therapeutics Inc
Research Protara Therapeutics Inc (TARA) on Bullrun: market cap USD 234.56M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTARA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 234.56M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 63.31M
- Free cash flow-USD 21.34M
Valuation Snapshot
latest market cap is USD 234.56M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 57.40M | -USD 56.46M | n/a | -1.34 | USD 49.66M | USD 3.36M | USD 196.41M |
| FY2024 | USD 0 | -USD 44.60M | -USD 35.87M | n/a | -2.17 | USD 162.80M | USD 4.48M | USD 167.13M |
| FY2023 | n/a | -USD 40.40M | -USD 37.60M | n/a | -3.57 | USD 39.59M | USD 5.47M | USD 68.32M |
| FY2022 | n/a | -USD 65.95M | -USD 26.58M | n/a | -5.86 | USD 24.13M | USD 6.82M | USD 102.08M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 234.56M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 285.62M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 185.04M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 21.37M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 30.20M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 75.84M | n/a | n/a | n/a |
About Protara Therapeutics Inc
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Protara Therapeutics Inc's market cap?
Protara Therapeutics Inc's market capitalization is USD 234.56M.
What does Protara Therapeutics Inc do?
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.